Dermatophagoides farinae-specific IgG responses in atopic dogs undergoing allergen-specific immunotherapy with aqueous vaccines

Chia-Chun Hou, Craig E. Griffin, Peter B. Hill

Research output: Contribution to journalArticlepeer-review

Abstract

The molecular and immunologic mechanisms associated with successful allergen-specific immunotherapy (ASIT) have not been completely elucidated. The aim of this study was to characterize the changes in Dermatophagoides farinae-specific IgG in atopic dogs undergoing ASIT using aqueous vaccines. Fifteen atopic dogs with a positive skin test reaction to D. farinae were treated with aqueous vaccines for a minimum of 2 months following a standard protocol. Serum samples were collected before and during therapy and used to probe Western blots containing separated proteins of D. farinae. IgG responses were detected using a polyclonal goat anticanine IgG antibody and a chromogenic substrate 3,3'-diaminobenzidine. The blots were analysed using a semiquantitative digital image analysis system that evaluated the number and molecular weight of bands, as well as their intensity, which was related to IgG concentration. Prior to ASIT, all dogs showed allergen-specific IgG responses to various antigens of D. farinae. During ASIT, there was a significant increase in the total quantity of D. farinae-specific IgG antibodies to various antigens from the mite (P = 0.015). Significant increases were observed for a 98-kDa band (P = 0.015), likely to be Der f 15; bands with molecular weights between 50 and 70 kDa (P = 0.012); and bands between 30 and 45 kDa (P = 0.035). These findings provide support for the hypothesis that ASIT induces IgG blocking antibodies to allergens known to be relevant in canine atopic dermatitis.

Original languageEnglish
Pages (from-to)215-220
Number of pages6
JournalVeterinary Dermatology
Volume19
Issue number4
DOIs
Publication statusPublished - Aug 2008

Fingerprint

Dive into the research topics of 'Dermatophagoides farinae-specific IgG responses in atopic dogs undergoing allergen-specific immunotherapy with aqueous vaccines'. Together they form a unique fingerprint.

Cite this